Acute pulmonary emboli in a patient on long-term dabigatran therapy

Annals of Pharmacotherapy

Volumn 47, Issue 4, 2013, Pages

  Rafferty, Joseph A ^a   Prom, Rathasen ^a   Kujawski, Stephanie Z ^b  

^a Mission Hospitals Incorporated   (United States)

^b University of North Carolina   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CELECOXIB; DABIGATRAN; ENOXAPARIN; WARFARIN;

AGED; ANTICOAGULANT THERAPY; ARTICLE; CASE REPORT; COMPRESSION STOCKING; COMPUTED TOMOGRAPHIC ANGIOGRAPHY; DRUG EFFICACY; DRUG SUBSTITUTION; DRUG TREATMENT FAILURE; DRUG WITHDRAWAL; DYSPNEA; EVENING DOSAGE; FEMALE; HEART ATRIUM FIBRILLATION; HOSPITAL ADMISSION; HUMAN; HYPERCOAGULABILITY; INTERNATIONAL NORMALIZED RATIO; LABORATORY TEST; LONG TERM CARE; LUNG EMBOLISM; MORNING DOSAGE; OBESITY; PATIENT COMPLIANCE; PLEURISY; PRIORITY JOURNAL; THORAX PAIN;

EID: 84876269724     PISSN: 10600280     EISSN: None     Source Type: Journal    
DOI: 10.1345/aph.1R752     Document Type: Article

References (25)

1. Ansell J, Hirsh J, Poller L, et al. The pharmacology and management of the vitamin K antagonists: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. Chest 2004;126:204S-33S.
2. Fuster V, Ryden LE, Cannom DS, et al. 2011 ACCF/AHA/HRS focused updates incorporated into the ACC/AHA/ESC 2006 guidelines for the management of patients with atrial fibrillation: a report of the American College of Cardiology Foundation/American Heart Association Task Force on practice guidelines. Circulation 2011;123:e269-367.
3. Anand SS, Yusuf S. Oral anticoagulant therapy in patients with coronary artery disease: a meta-analysis. JAMA 1999;282:2058-67.
4. Salem DN, O'Gara PT, Madias C, et al. Valvular and structural heart disease: American College of Chest Physicians evidence-based clinical practice guidelines (8th edition). Chest 2008;133:593S-629S.
5. Kearon C, Akl EA, Comerota AJ, et al. Antithrombotic therapy for VTE disease: antithrombotic therapy and prevention of thrombosis: American College of Chest Physicians evidence-based clinical practice guidelines (9th ed). Chest 2012;141:e419S-94S.
6. Connolly SJ, Ezekowitz MD, Yusuf S, et al. Dabigatran versus warfarin in patients with atrial fibrillation. N Engl J Med 2009;361:1139-51.
7. Schulman S, Kearon C, Kakkar AK, et al. Dabigatran versus warfarin in the treatment of acute venous thromboembolism. N Engl J Med 2009; 361:2342-52.
8. Schulman S, Kakkar A, Schellong S, et al. A randomized trial of dabigatran versus warfarin in the treatment of acute venous thromboembolism (RECOVER II). Blood (ASH Annual Meeting Abstracts) 2011;118:95-6.
9. Schulman S, Baanstra D, Eriksson H, et al. Dabigatran vs placebo for extended maintenance therapy of venous thromboembolism (abstract OMO-037). J Thromb Haemost 2011;9:22.
10. Schulman S, Eriksson H, Goldhaber S, et al. Dabigatran or warfarin for extended maintenance therapy of venous thromboembolism (abstract OTH-033). J Thromb Haemost 2011;9:731-2.
11. Eriksson BI, Dahl OE, Rosencher N, et al. Dabigatran etexilate versus enoxaparin for prevention of venous thromboembolism after total hip replacement: a randomised, double-blind, non-inferiority trial. Lancet 2007; 370:949-56.
12. Eriksson BI, Dahl OE, Rosencher N, et al. Oral dabigatran etexilate vs subcutaneous enoxaparin for the prevention of venous thromboembolism after total knee replacement: the RE-MODEL randomized trial. J Thromb Haemost 2007;5:2178-85.
13. Ginsberg JS, Davidson BL, Comp PC, et al. Oral thrombin inhibitor da-biga tran etexilate vs North American enoxaparin regimen for prevention of venous thromboembolism after knee arthroplasty surgery. J Arthroplasty 2009;24:1-9.
14. Anderson FA Jr, Wheeler HB, Goldberg RJ, et al. A population-based perspective of the hospital incidence and case-fatality rates of deep vein thrombosis and pulmonary embolism. The Worcester DVT Study. Arch Intern Med 1991;151:933-8.
15. Barbar S, Noventa F, Rosetto V, et al. A risk assessment model for the identification of hospitalized medical patients at risk for venous thromboembolism: the Padua Prediction Score. J Thromb Haemost 2010;8: 2450-7.
16. Stangier J. Clinical pharmacokinetics and pharmacodynamics of the oral direct thrombin inhibitor dabigatran etexilate. Clin Pharmacokinet 2008; 47:285-95.
17. Stangier J, Stahle H, Rathgen K, et al. Pharmacokinetics and pharmacodynamics of the direct oral thrombin inhibitor dabigatran in healthy elderly subjects. Clin Pharmacokinet 2008;47:47-59.
18. Stangier J, Eriksson BI, Dahl OE, et al. Pharmacokinetic profile of the oral direct thrombin inhibitor dabigatran etexilate in healthy volunteers and patients undergoing total hip replacement. J Clin Pharmacol 2005;45: 555-63.
19. Liesenfeld KH, Lehr T, Dansirikul C, et al. Population pharmacokinetic analysis of the oral thrombin inhibitor dabigatran etexilate in patients with non-valvular atrial fibrillation from the RE-LY trial. J Thromb Haemost 2011;9:2168-75.
20. Food and Drug Administration. Briefing information for the September 20, 2010, meeting of the Cardiovascular and Renal Drugs Advisory Committee. http://www.fda.gov/AdvisoryCommittees/CommitteesMeeting Materials/Drugs/CardiovascularandRenalDrugsAdvisoryCommittee/ucm 226008.htm (accessed 2012 Nov 25).
21. Blech S, Ebner T, Ludwig-Schwellinger E, et al. The metabolism and disposition of the oral direct thrombin inhibitor, dabigatran, in humans. Drug Metab Dispos 2008;36:386-99.
22. Product information. Pradaxa (dabigatran etexilate). Ridgefield, CT: Boehringer Ingelheim Pharmaceuticals, November 2011.
23. Data on file (H019955, H019959). Ridgefield, CT: Boehringer Ingelheim Pharmaceuticals, Inc.
24. Product information. Xarelto (rivaroxaban). Titusville, NJ: Janssen Pharmaceuticals, Inc., November 2012.
25. Product information. Eliquis (apixaban). Princeton, NJ: Bristol-Myers Squibb Company, December 2012.